Analyst Price Targets — BDTX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| January 16, 2026 11:54 am | Kelsey Goodwin | Piper Sandler | $8.00 | $2.67 | TheFly | Black Diamond Therapeutics price target lowered to $8 from $9 at Piper Sandler |
| October 15, 2025 8:31 pm | Laura Prendergast | Stifel Nicolaus | $8.00 | $4.14 | TheFly | Black Diamond Therapeutics resumed with a Buy at Stifel |
| September 3, 2025 8:15 pm | Brad Canino | Guggenheim | $8.00 | $2.88 | TheFly | Black Diamond Therapeutics initiated with a Buy at Guggenheim |
| July 31, 2024 8:18 am | Laura Prendergast | Raymond James | $20.00 | $5.91 | TheFly | Black Diamond Therapeutics initiated with an Outperform at Raymond James |
| June 3, 2024 8:52 am | Joseph Calanzaro | Piper Sandler | $12.00 | $4.78 | StreetInsider | Piper Sandler Reiterates Overweight Rating on Black Diamond Therapeutics (BDTX) |
| May 16, 2024 6:12 am | Robert Burns | H.C. Wainwright | $11.00 | $5.44 | TheFly | Black Diamond price target lowered to $11 from $12 at H.C. Wainwright |
| April 8, 2024 7:07 am | Robert Driscoll | Wedbush | $16.00 | $5.06 | StreetInsider | Black Diamond Therapeutics (BDTX) PT Raised to $16 at Wedbush |
| March 18, 2024 6:38 am | Raghuram Selvaraju | H.C. Wainwright | $12.00 | $4.70 | StreetInsider | Black Diamond Therapeutics (BDTX) PT Raised to $12 at H.C. Wainwright |
Latest News for BDTX
CAMBRIDGE, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, including silevertinib, a potential best-in-class brain-penetrant epidermal growth factor receptor (EGFR) inhibitor, today announced that its Chief Scientific Officer, Elizabeth Buck,…
CAMBRIDGE, Mass., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, including silevertinib, a potential best-in-class brain-penetrant epidermal growth factor receptor (EGFR) inhibitor, today reported financial results for the second quarter ended June…
Black Diamond Therapeutics trades below cash value, offering a compelling risk/reward profile in precision oncology. Silevertinib, BDTX's lead asset, showed strong Phase 2 results with 60% ORR and 86% CNS ORR, targeting NSCLC patients underserved by legacy TKIs. Despite mega-cap competition, BDTX's $118M cash runway, potential non-dilutive milestone payments, and MasterKey platform underpin a Buy rating.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for BDTX.
U.S. House Trading
No House trades found for BDTX.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.